| Literature DB >> 32206007 |
De-Feng Li1, Feng Xiong1, Zhi-Chao Yu1, Hai-Yang Zhang1, Ting-Ting Liu1, Yan-Hui Tian1, Rui-Yue Shi1, Ming-Guang Lai1, Yang Song1, Zheng-Lei Xu1, Ding-Guo Zhang1, Jun Yao1, Li-Sheng Wang2.
Abstract
BACKGROUND: Peroral endoscopic myotomy (POEM) is a promising therapeutic modality for esophageal achalasia worldwide. However, clinical failure and adverse events of POEM have still been concerned. AIM: To compare the efficacy and safety of a novel mark-guided POEM with standard POEM.Entities:
Keywords: Achalasia; Adverse event; Efficacy; Endoscopy; Mark-guided peroral endoscopic myotomy; Standard peroral endoscopic myotomy
Mesh:
Year: 2020 PMID: 32206007 PMCID: PMC7081014 DOI: 10.3748/wjg.v26.i9.973
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1Flow chart.
Baseline characteristics and comparison of procedurerelated parameters
| Sex | |||
| Male ( | 33 (51.6%) | 36 (52.2%) | 0.94 |
| Female ( | 31 (48.4%) | 33 (47.8%) | |
| Age (yr) | 33.5 (28-48.75) | 40 (30-47.75) | 0.22 |
| Achalasia Type | |||
| I | 21 (32.8%) | 23 (33.3%) | 0.98 |
| II | 36 (56.3%) | 38 (55.1%) | |
| III | 7 (10.9%) | 8 (11.6%) | |
| Disease duration (mo) | 32.5 (23-49.50) | 33 (22.5-49.50) | 0.95 |
| Eckardt score | 9.0 (8-9.75) | 8.0 (7-9) | 0.32 |
| Barium esophagraphy | |||
| Height (cm) | 8 (8-9) | 8 (7-9) | 0.55 |
| Diameter (cm) | 5 (4-6) | 5 (5-6) | 0.29 |
| HRM (mmHg) | 38 (28-41) | 38 (28-41.5) | 0.64 |
| GERDQ score | 7 (6-9) | 7 (6-8.5) | 0.74 |
| SF-36 score | 47.22 ± 7.25 | 46.81 ± 7.60 | 0.75 |
| Procedure duration (min) | 40 (38-43) | 49 (47-51) | < 0.001 |
| Technical success ( | 64 (100%) | 69 (100%) | 1 |
| Postoperative stay (d) | 1 (1-2) | 1 (1-2) | 0.56 |
| Perforation ( | 0 | 0 | 1 |
| Bleeding ( | 0 | 0 | 1 |
POEM: Peroral endoscopic myotomy; HRM: High-resolution manometry; GERDQ: Gastroesophageal reflux disease questionnaire; SF-36: 36-Item Short-Form Health Survey.
Figure 2High-resolution manometry, Eckart score and 36-Item Short-Form Health Survey scores at 3-mo follow-up in the mark-guided peroral endoscopic myotomy group and standard peroral endoscopic myotomy group. A-D: The pre-operative high-resolution manometry and Eckart scores were significantly decreased compared with the postoperative values in the two groups (all P < 0.001); E, F: The pre-operative 36-Item Short-Form Health Survey scores were significantly improved compared with the postoperative values in both groups (all P < 0.001).
Primary and secondary outcomes in patients at 3 mo follow-up
| Overall clinical success ( | 63 (98.4%) | 68 (98.6%) | 0.3 |
| Eckart score | 1 (1-2) | 1 (1-2) | 0.78 |
| GERDQ score | 6 (5-9) | 6 (5-7) | 0.35 |
| SF-36 score | 78 (76-80) | 78 (75-80.5) | 0.87 |
| Barium esophagraphy | |||
| Height (cm) | 3 (2-4) | 3 (2-4) | 0.94 |
| Diameter (cm) | 2 (2-2.5) | 2 (2-2.75) | 0.86 |
| HRM (mmHg) | 12.2 ± 2.37 | 12.06 ± 1.93 | 0.7 |
| Reflux symptom ( | |||
| Yes | 7 (10.9%) | 17 (24.6%) | 0.04 |
| No | 57 (89.1%) | 52(75.4%) | |
| PPI use ( | |||
| Yes | 8 (12.7%) | 19 (27.5%) | 0.03 |
| No | 56 (87.3%) | 60 (72.5%) |
POEM: Peroral endoscopic myotomy; HRM: High-resolution manometry; GERDQ: Gastroesophageal reflux disease questionnaire; SF-36: 36-Item Short-Form Health Survey; PPI: Proton pump inhibitor.
Figure 3Barium esophagography at 3-mo follow-up in the mark-guided peroral endoscopic myotomy group and standard peroral endoscopic myotomy group. A-D: The post-operative height and diameter of barium esophagography were significantly decreased compared with the pre-operative values in the two groups (all P < 0.001); E: The pre-operative Gastroesophageal reflux disease questionnaire score was significantly decreased compared with the post-operative value in the standard peroral endoscopic myotomy group (P = 0.01); F: No significant difference was observed between pre-operative and post-operative values in the mark-guided peroral endoscopic myotomy group (P = 0.09).
Primary and secondary outcomes in patients at 12 mo follow-up
| Overall clinical success ( | 55 (93.2%) | 54 (91.5%) | 0.73 |
| Eckart score | 1 (1-2) | 1 (1-2) | 0.9 |
| GERDQ score | 7 (6-9) | 6 (6-9) | 0.67 |
| SF-36 score | 75 (67-78) | 74 (70-78) | 0.94 |
| Reflux symptom ( | |||
| Yes | 10 (16.9%) | 22 (37.3%) | 0.01 |
| No | 49 (83.1%) | 37 (62.7%) | |
| PPI use ( | |||
| Yes | 11 (18.6%) | 24 (40.7%) | 0.009 |
| No | 48 (81.4%) | 35 (59.3%) |
POEM: Peroral endoscopic myotomy; GERDQ: Gastroesophageal reflux disease questionnaire; SF-36: 36-Item Short-Form Health Survey; PPI: Proton pump inhibitor.
Primary and secondary outcomes in patients at 24 mo follow-up
| Overall clinical success ( | 44 (92.7%) | 47 (92.2%) | 0.93 |
| Eckart score | 1 (1-2) | 1 (1-2) | 0.92 |
| GERDQ score | 7 (6-9) | 7 (6-9) | 0.74 |
| SF-36 score | 77 (71-80) | 76 (72-80) | 0.73 |
| Reflux symptom ( | |||
| Yes | 13 (27.1%) | 24(47.1%) | 0.04 |
| No | 35(72.9%) | 27 (52.9%) | |
| PPI use ( | |||
| Yes | 14 (29.2%) | 26 (51%) | 0.02 |
| No | 34 (70.8%) | 25 (49%) |
POEM: Peroral endoscopic myotomy; GERDQ: Gastroesophageal reflux disease questionnaire; SF-36: 36-Item Short-Form Health Survey; PPI: Proton pump inhibitor.